MA45615A - PHARMACEUTICAL COMPOSITIONS AND THEIR USES AGAINST LYSOSOMAL OVERLOAD DISEASES - Google Patents

PHARMACEUTICAL COMPOSITIONS AND THEIR USES AGAINST LYSOSOMAL OVERLOAD DISEASES

Info

Publication number
MA45615A
MA45615A MA045615A MA45615A MA45615A MA 45615 A MA45615 A MA 45615A MA 045615 A MA045615 A MA 045615A MA 45615 A MA45615 A MA 45615A MA 45615 A MA45615 A MA 45615A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
overload diseases
uses against
against lysosomal
lysosomal overload
Prior art date
Application number
MA045615A
Other languages
French (fr)
Other versions
MA45615B1 (en
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA45615A publication Critical patent/MA45615A/en
Publication of MA45615B1 publication Critical patent/MA45615B1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le traitement des troubles du stockage lysosomal (lsd) comprenant l'administration d'acétyl-leucine ou d'un sel pharmaceutiquement acceptable de celle-ci.The present invention relates to the treatment of lysosomal storage disorders (LSD) comprising the administration of acetyl-leucine or a pharmaceutically acceptable salt thereof.

MA45615A 2016-08-11 2017-08-11 Pharmaceutical compositions and their uses against lysosomal overload diseases MA45615B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders

Publications (2)

Publication Number Publication Date
MA45615A true MA45615A (en) 2019-05-15
MA45615B1 MA45615B1 (en) 2021-03-31

Family

ID=56985904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45615A MA45615B1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and their uses against lysosomal overload diseases

Country Status (2)

Country Link
GB (1) GB201613828D0 (en)
MA (1) MA45615B1 (en)

Also Published As

Publication number Publication date
GB201613828D0 (en) 2016-09-28
MA45615B1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
MA43876A (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USES AGAINST LYSOSOMAL OVERLOAD DISEASES
MX2021004431A (en) Novel processes.
MX2020006460A (en) DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS.
MA41496B1 (en) Pharmaceutical compositions comprising n- (3,5-dimethoxyphenyl) -n '- (1-methylethyl) -n- [3- (1-methyl-1h-pyrazol-4-yl) quinoxalin-6-yl] ethane-1, 2-diamine
MA44674A (en) BROMODOMAIN INHIBITORS
MX2020010390A (en) PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS.
WO2015120110A3 (en) Novel pharmaceutical formulations
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
MA33593B1 (en) Heterocyclic compounds and their uses
MX2020006459A (en) DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS.
MA43828A (en) THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
MA34083B1 (en) PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND USE THEREOF AS THERAPEUTIC AGENTS
MA44935A1 (en) Pharmaceutical compositions containing an alpha 4 integrin antagonist, used for the treatment of inflammatory conditions of the eye
MA40875B1 (en) Substituted 2,4-diamino-quinoline as new anticancer agents
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
MA39447B1 (en) Pirlindole or its pharmaceutically acceptable salts for use in medicine
MA45639B1 (en) Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
EA201600486A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING ANTIKOAGULANT N- (5-CHLORPYRIDIN-2-IL) -2 - ({4- [ETHANIMIDOIL (METHYL) AMINO] BENZOIL} AMINO) -5-METHYLBENZAMIDE
MA39448B1 (en) (r) -pirlindole and its pharmaceutically acceptable salts for medical use
MA38215A1 (en) Topical ophthalmic pharmaceutical composition containing regorafenib
MY195054A (en) Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and use Thereof
MA45615A (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USES AGAINST LYSOSOMAL OVERLOAD DISEASES
MX2017012188A (en) Bace1 inhibitors.
MA46778B1 (en) Intranasal composition comprising betahistine
HRP20230693T1 (en) Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients